PT - JOURNAL ARTICLE AU - Starrfelt, Jostein AU - Buanes, Eirik Alnes AU - Juvet, Lene Kristine AU - Lyngstad, Trude Marie AU - Isaksson Rø, Gunnar Øyvind AU - Veneti, Lamprini AU - Meijerink, Hinta TI - Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January – September 2021 AID - 10.1101/2021.11.12.21266222 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.12.21266222 4099 - http://medrxiv.org/content/early/2021/11/12/2021.11.12.21266222.short 4100 - http://medrxiv.org/content/early/2021/11/12/2021.11.12.21266222.full AB - Background SARS-CoV-2 vaccines show high effectiveness against infection and (severe) disease. However, few studies estimate population level vaccine effectiveness against multiple COVID-19 outcomes, by age and including homologous and heterologous vaccine regimens.Methods Using Cox proportional hazard models on data from 4 293 544 individuals (99% of Norwegian adults), we estimated overall, age-, and product-specific vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, ICU admission and death in Norway, using data from national registries. Vaccine status was included as time-dependent variable and we adjusted for sex, pre-existing medical conditions, country of birth, county of residence, and crowded living conditions.Findings Adjusted vaccine effectiveness among fully vaccinated is 72·1% (71·2–73·0) against SARS-CoV-2 infection, 92·9% (91·2–94·2) against hospitalisation, 95·5% (92·6–97·2) against ICU admission, and 88·0% (82·5–91·8) against death. Among partially vaccinated, the effectiveness is 24·3% (22·3–26·2) against infection and 82·7% (77·7–86·6) against hospitalisation. Vaccine effectiveness against infection is 84·7% (83·1-86·1) for heterologous mRNA vaccine regimens, 78·3% (76·8-79·7) for Spikevax (Moderna; mRNA-1273), 69·7% (68·6-70·8) for Comirnaty (Pfizer/BioNTech; BNT162b2), and 60·7% (57·5-63·6) for Vaxzevria (AstraZeneca; ChAdOx nCoV-19; AZD1222) with a mRNA dose among fully vaccinated.Interpretation We demonstrate good protection against SARS-CoV-2 infection and severe disease in fully vaccinated, including heterologous vaccine regimens, which could facilitate rapid immunization. Partially vaccinated were less likely to get severe disease than unvaccinated, though protection against infection was not as high, which could be essential in making vaccine prioritisation policies especially when availability is limited.Funding Norwegian Institute of Public Health, Helse Bergen Health TrustCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study was performed without external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by Regional Committees for Medical and Health Research Ethics (REC) South East, Norway (reference number 122745).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLegal restrictions prevent sharing the dataset used in this study. However, researchers are able to request access to linked data from the same registries, as per normal procedure for conducting health research on registry data in Norway. Further information on the preparedness registry, including access to data from each data source, is available at https://www.fhi.no/en/id/infectiousdiseases/coronavirus/emergency-preparedness-register-for-covid-19/